Compare Organon & Co. Common Stock (OGN) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Tidewater Inc — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Tidewater Inc trades at $83.1 (market cap $4.12B). The key difference: Organon & Co. Common Stock and Tidewater Inc are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Tidewater Inc for 27 Days on average.
| OGN | TDW | |
|---|---|---|
Market Cap | $3.61B | $4.12B |
Volume | 1,808,049 | 718,273 |
Sector | Health | Energy |
52-Week High | $13.81 | $100.61 |
52-Week Low | $5.70 | $47.29 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $11.03B | $4.16B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Tidewater (TDW) trades at $86.97, up 0.6% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with an 18.34% net income margin and 19.49% ROE, though recent quarterly EPS missed expectations. The acquisition of Wilson Sons Ultratug (Business Wire, 2026-08-31) expands its offshore services footprint. Analyst consensus price target is $105.50, implying potential upside from current levels.
The outlook is cautiously optimistic, supported by solid cash flow and institutional interest, but risks include earnings volatility and competitive pressures. Revenue declined to $1.3B in 2026 from $1.4B in 2025, and profit margins compressed, requiring monitoring of operational execution amid energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
